{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:40:36Z","timestamp":1792525236825,"version":"4.5.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82402315"],"award-info":[{"award-number":["82402315"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82202200"],"award-info":[{"award-number":["82202200"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s12149-026-02250-9","type":"journal-article","created":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T15:41:48Z","timestamp":1782920508000},"page":"1339-1349","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Prognostic Value of 68Ga-PSMA and 18F-FDG PET\/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-EB-PSMA"],"prefix":"10.1007","volume":"40","author":[{"given":"Xingting","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingming","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongfei","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaohui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guochang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8281-9177","authenticated-orcid":false,"given":"Jie","family":"Zang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,1]]},"reference":[{"key":"2250_CR1","first-page":"e70043","volume":"76","author":"RL Siegel","year":"2026","unstructured":"Siegel RL, Kratzer TB, Wagle NS, Sung H, Jemal A. Cancer statistics, 2026. CA Cancer J Clin. 2026;76:e70043.","journal-title":"CA Cancer J Clin"},{"key":"2250_CR2","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/jama.2025.0228","volume":"333","author":"R Raychaudhuri","year":"2025","unstructured":"Raychaudhuri R, Lin DW, Montgomery RB. Prostate Cancer: A Review. JAMA. 2025;333:1433\u201346.","journal-title":"JAMA"},{"key":"2250_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1200\/OP-25-00037","volume":"21","author":"ZI Ozay","year":"2025","unstructured":"Ozay ZI, Swami U, Agarwal N. Challenges in the Management of Advanced Prostate Cancer. JCO Oncol Pract. 2025;21:447\u20139.","journal-title":"JCO Oncol Pract"},{"key":"2250_CR4","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","volume":"397","author":"MS Hofman","year":"2021","unstructured":"Hofman MS, Emmett L, Sandhu S, Iravani A, Joshua AM, Goh JC, et al. [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial. Lancet. 2021;397:797\u2013804.","journal-title":"Lancet"},{"key":"2250_CR5","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett L, Subramaniam S, Crumbaker M, Nguyen A, Joshua AM, Weickhardt A, et al. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 2024;25:563\u201371.","journal-title":"Lancet Oncol"},{"key":"2250_CR6","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor O, de Bono J, Chi KN, Fizazi K, Herrmann K, Rahbar K, et al. Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. N Engl J Med. 2021;385:1091\u2013103.","journal-title":"N Engl J Med"},{"key":"2250_CR7","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1158\/1078-0432.CCR-22-2875","volume":"29","author":"J Fallah","year":"2023","unstructured":"Fallah J, Agrawal S, Gittleman H, Fiero MH, Subramaniam S, John C, et al. FDA Approval Summary: Lutetium Lu 177 Vipivotide Tetraxetan for Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2023;29:1651\u20137.","journal-title":"Clin Cancer Res"},{"key":"2250_CR8","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris MJ, Castellano D, Herrmann K, de Bono JS, Shore ND, Chi KN, et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet. 2024;404:1227\u201339.","journal-title":"Lancet"},{"key":"2250_CR9","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S1470-2045(21)00274-6","volume":"22","author":"A Gafita","year":"2021","unstructured":"Gafita A, Calais J, Grogan TR, Hadaschik B, Wang H, Weber M, et al. Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study. Lancet Oncol. 2021;22:1115\u201325.","journal-title":"Lancet Oncol"},{"key":"2250_CR10","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.2967\/jnumed.121.263441","volume":"63","author":"M Hotta","year":"2022","unstructured":"Hotta M, Gafita A, Czernin J, Calais J. Outcome of Patients with PSMA PET\/CT Screen Failure by VISION Criteria and Treated with 177Lu-PSMA Therapy: A Multicenter Retrospective Analysis. J Nucl Med. 2022;63:1484\u20138.","journal-title":"J Nucl Med"},{"key":"2250_CR11","doi-asserted-by":"publisher","first-page":"e233460","DOI":"10.1148\/radiol.233460","volume":"312","author":"PH Kuo","year":"2024","unstructured":"Kuo PH, Morris MJ, Hesterman J, Kendi AT, Rahbar K, Wei XX, et al. Quantitative 68PSMA-11 PET and Clinical Outcomes in Metastatic Castration-resistant Prostate Cancer Following 177Lu-PSMA-617 (VISION Trial). Radiology. 2024;312:e233460.","journal-title":"Radiology"},{"key":"2250_CR12","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1007\/s00259-020-05160-8","volume":"48","author":"K Michalski","year":"2021","unstructured":"Michalski K, Ruf J, Goetz C, Seitz AK, Buck AK, Lapa C, Hartrampf PE. Prognostic implications of dual tracer PET\/CT: PSMA ligand and [18F]FDG PET\/CT in patients undergoing [177Lu]PSMA radioligand therapy. Eur J Nucl Med Mol Imaging. 2021;48:2024\u201330.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2250_CR13","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","volume":"23","author":"JP Buteau","year":"2022","unstructured":"Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022;23:1389\u201397.","journal-title":"Lancet Oncol"},{"key":"2250_CR14","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1007\/s00259-025-07198-y","volume":"52","author":"T Telli","year":"2025","unstructured":"Telli T, Lopes L, Karpinski M, Pabst KM, Gr\u00fcnwald V, Shi K, et al. Prognostic value of [18F]FDG- and PSMA-PET in patients evaluated for [177Lu]Lu-PSMA therapy of mCRPC. Eur J Nucl Med Mol Imaging. 2025;52:3199\u2013210.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2250_CR15","doi-asserted-by":"publisher","first-page":"3213","DOI":"10.1021\/acs.bioconjchem.8b00556","volume":"29","author":"Z Wang","year":"2018","unstructured":"Wang Z, Tian R, Niu G, Ma Y, Lang L, Szajek LP, et al. Single Low-Dose Injection of Evans Blue Modified PSMA-617 Radioligand Therapy Eliminates Prostate-Specific Membrane Antigen Positive Tumors. Bioconjug Chem. 2018;29:3213\u201321.","journal-title":"Bioconjug Chem"},{"key":"2250_CR16","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1007\/s00259-018-4096-y","volume":"46","author":"J Zang","year":"2019","unstructured":"Zang J, Fan X, Wang H, Liu Q, Wang J, Li H, et al. First-in-human study of 177Lu-EB-PSMA-617 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:148\u201358.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2250_CR17","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00259-023-06470-3","volume":"51","author":"J Zang","year":"2024","unstructured":"Zang J, Wang G, Zhao T, Liu H, Lin X, Yang Y, et al. A phase 1 trial to determine the maximum tolerated dose and patient-specific dosimetry of [177Lu]Lu-LNC1003 in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2024;51:871\u201382.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2250_CR18","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.2967\/jnumed.120.242263","volume":"61","author":"J Zang","year":"2020","unstructured":"Zang J, Liu Q, Sui H, Wang R, Jacobson O, Fan X, et al. 177Lu-EB-PSMA Radioligand Therapy with Escalating Doses in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2020;61:1772\u20138.","journal-title":"J Nucl Med"},{"key":"2250_CR19","doi-asserted-by":"publisher","first-page":"611","DOI":"10.2967\/jnumed.122.264857","volume":"64","author":"G Wang","year":"2023","unstructured":"Wang G, Zang J, Jiang Y, Liu Q, Sui H, Wang R, et al. A Single-Arm, Low-Dose, Prospective Study of 177Lu-EB-PSMA Radioligand Therapy in Patients with Metastatic Castration-Resistant Prostate Cancer. J Nucl Med. 2023;64:611\u20137.","journal-title":"J Nucl Med"},{"key":"2250_CR20","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1097\/RLU.0000000000002575","volume":"44","author":"J Wang","year":"2019","unstructured":"Wang J, Zang J, Wang H, Liu Q, Li F, Lin Y, et al. Pretherapeutic 68Ga-PSMA-617 PET May Indicate the Dosimetry of 177Lu-PSMA-617 and 177Lu-EB-PSMA-617 in Main Organs and Tumor Lesions. Clin Nucl Med. 2019;44:431\u20138.","journal-title":"Clin Nucl Med"},{"key":"2250_CR21","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","volume":"34","author":"HI Scher","year":"2016","unstructured":"Scher HI, Morris MJ, Stadler WM, Higano C, Basch E, Fizazi K, et al. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. J Clin Oncol. 2016;34:1402\u201318.","journal-title":"J Clin Oncol"},{"key":"2250_CR22","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.eururo.2021.03.004","volume":"80","author":"MS Sadaghiani","year":"2021","unstructured":"Sadaghiani MS, Sheikhbahaei S, Werner RA, Pienta KJ, Pomper MG, Solnes LB, et al. A Systematic Review and Meta-analysis of the Effectiveness and Toxicities of Lutetium-177-labeled Prostate-specific Membrane Antigen-targeted Radioligand Therapy in Metastatic Castration-Resistant Prostate Cancer. Eur Urol. 2021;80:82\u201394.","journal-title":"Eur Urol"},{"key":"2250_CR23","doi-asserted-by":"publisher","first-page":"560","DOI":"10.2967\/jnumed.121.262552","volume":"63","author":"S Pathmanandavel","year":"2022","unstructured":"Pathmanandavel S, Crumbaker M, Yam AO, Nguyen A, Rofe C, Hovey E, et al. 177Lu-PSMA-617 and Idronoxil in Men with End-Stage Metastatic Castration-Resistant Prostate Cancer (LuPIN): Patient Outcomes and Predictors of Treatment Response in a Phase I\/II Trial. J Nucl Med. 2022;63:560\u20136.","journal-title":"J Nucl Med"},{"key":"2250_CR24","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S1470-2045(24)00440-6","volume":"25","author":"AA Azad","year":"2024","unstructured":"Azad AA, Bressel M, Tan H, Voskoboynik M, Suder A, Weickhardt AJ, et al. Sequential [177Lu]Lu-PSMA-617 and docetaxel versus docetaxel in patients with metastatic hormone-sensitive prostate cancer (UpFrontPSMA): a multicentre, open-label, randomised, phase 2 study. Lancet Oncol. 2024;25:1267\u201376.","journal-title":"Lancet Oncol"},{"key":"2250_CR25","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.7150\/thno.93249","volume":"14","author":"D Arbuznikova","year":"2024","unstructured":"Arbuznikova D, Klotsotyra A, Uhlmann L, Domogalla LC, Steinacker N, Mix M, et al. Exploring the role of combined external beam radiotherapy and targeted radioligand therapy with [177Lu]Lu-PSMA-617 for prostate cancer - from bench to bedside. Theranostics. 2024;14:2560\u201372.","journal-title":"Theranostics"},{"key":"2250_CR26","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1007\/s00259-020-05022-3","volume":"48","author":"V Kramer","year":"2021","unstructured":"Kramer V, Fernandez R, Lehnert W, Jimenez-Franco LD, Soza-Ried C, Eppard E, et al. Biodistribution and dosimetry of a single dose of albumin-binding ligand [177Lu]Lu-PSMA-ALB-56 in patients with mCRPC. Eur J Nucl Med Mol Imaging. 2021;48:893\u2013903.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2250_CR27","doi-asserted-by":"publisher","first-page":"2794","DOI":"10.1007\/s00259-024-06721-x","volume":"51","author":"L Li","year":"2024","unstructured":"Li L, Wang J, Wang G, Wang R, Jin W, Zang J, et al. Comparison of novel PSMA-targeting [177Lu]Lu-P17-087 with its albumin binding derivative [177Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study. Eur J Nucl Med Mol Imaging. 2024;51:2794\u2013805.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2250_CR28","doi-asserted-by":"publisher","first-page":"2431","DOI":"10.1007\/s00259-025-07102-8","volume":"52","author":"P Ritt","year":"2025","unstructured":"Ritt P, Fernandez R, Soza-Ried C, Nicolai H, Amaral H, Krieger K, et al. Biodistribution and dosimetry of [177Lu]Lu-SibuDAB in patients with metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2025;52:2431\u201343.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2250_CR29","doi-asserted-by":"publisher","first-page":"1737","DOI":"10.2967\/jnumed.122.265155","volume":"64","author":"V Murthy","year":"2023","unstructured":"Murthy V, Gafita A, Thin P, Nguyen K, Grogan T, Shen J, et al. Prognostic Value of End-of-Treatment PSMA PET\/CT in Patients Treated with 177Lu-PSMA Radioligand Therapy: A Retrospective, Single-Center Analysis. J Nucl Med. 2023;64:1737\u201343.","journal-title":"J Nucl Med"},{"key":"2250_CR30","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1007\/s00259-020-05040-1","volume":"48","author":"R Seifert","year":"2021","unstructured":"Seifert R, Kessel K, Schlack K, Weber M, Herrmann K, Spanke M, et al. PSMA PET total tumor volume predicts outcome of patients with advanced prostate cancer receiving [177Lu]Lu-PSMA-617 radioligand therapy in a bicentric analysis. Eur J Nucl Med Mol Imaging. 2021;48:1200\u201310.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2250_CR31","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1007\/s00259-021-05594-8","volume":"49","author":"F Rosar","year":"2022","unstructured":"Rosar F, Wenner F, Khreish F, Dewes S, Wagenpfeil G, Hoffmann MA, et al. Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET\/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy. Eur J Nucl Med Mol Imaging. 2022;49:1584\u201394.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2250_CR32","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00259-018-4236-4","volume":"46","author":"B Grubmuller","year":"2019","unstructured":"Grubmuller B, Senn D, Kramer G, Baltzer P, D\u2019Andrea D, Grubmuller KH, et al. Response assessment using 68Ga-PSMA ligand PET in patients undergoing 177Lu-PSMA radioligand therapy for metastatic castration-resistant prostate cancer. Eur J Nucl Med Mol Imaging. 2019;46:1063\u201372.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2250_CR33","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","volume":"23","author":"JP Buteau","year":"2022","unstructured":"Buteau JP, Martin AJ, Emmett L, Iravani A, Sandhu S, Joshua AM, et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 2022;23:1389\u201397.","journal-title":"Lancet Oncol"},{"key":"2250_CR34","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2967\/jnumed.122.264104","volume":"64","author":"S Pathmanandavel","year":"2023","unstructured":"Pathmanandavel S, Crumbaker M, Nguyen A, Yam AO, Wilson P, Niman R, et al. The Prognostic Value of Posttreatment 68Ga-PSMA-11 PET\/CT and 18F-FDG PET\/CT in Metastatic Castration-Resistant Prostate Cancer Treated with 177Lu-PSMA-617 and NOX66 in a Phase I\/II Trial (LuPIN). J Nucl Med. 2023;64:69\u201374.","journal-title":"J Nucl Med"},{"key":"2250_CR35","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1007\/s00259-022-05882-x","volume":"49","author":"A Gafita","year":"2022","unstructured":"Gafita A, Rauscher I, Fendler WP, Murthy V, Hui W, Armstrong WR, et al. Measuring response in metastatic castration-resistant prostate cancer using PSMA PET\/CT: comparison of RECIST 1.1, aPCWG3, aPERCIST, PPP, and RECIP 1.0 criteria. Eur J Nucl Med Mol Imaging. 2022;49:4271\u201381.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2250_CR36","first-page":"1945","volume":"65","author":"RA Demirci","year":"2024","unstructured":"Demirci RA, Gulati R, Hawley JE, Yezefski T, Haffner MC, Cheng HH, et al. SPECT\/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving 177Lu-PSMA-617. J Nucl Med. 2024;65:1945\u201351.","journal-title":"J Nucl Med"},{"key":"2250_CR37","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.2967\/jnumed.125.269640","volume":"66","author":"R Kashyap","year":"2025","unstructured":"Kashyap R, Buteau JP, Bressel M, Eifer M, Bollampally N, Jackson P, et al. Prognostic Value of Posttherapy SPECT\/CT for Overall Survival in Patients Undergoing [177Lu]Lu-PSMA-617 Radiopharmaceutical Therapy: Results from 3 Clinical Trials. J Nucl Med. 2025;66:1265\u201370.","journal-title":"J Nucl Med"},{"key":"2250_CR38","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1007\/s00259-023-06476-x","volume":"51","author":"C Burgard","year":"2024","unstructured":"Burgard C, Hein C, Blickle A, Bartholoma M, Maus S, Petto S, et al. Change in total lesion PSMA (TLP) during [177Lu]Lu-PSMA-617 radioligand therapy predicts overall survival in patients with mCRPC: monocentric evaluation of a prospective registry. Eur J Nucl Med Mol Imaging. 2024;51:885\u201395.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2250_CR39","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.2967\/jnumed.123.265952","volume":"64","author":"TA Hope","year":"2023","unstructured":"Hope TA, Antonarakis ES, Bodei L, Calais J, Iravani A, Jacene H, et al. SNMMI Consensus Statement on Patient Selection and Appropriate Use of 177Lu-PSMA-617 Radionuclide Therapy. J Nucl Med. 2023;64:1417\u201323.","journal-title":"J Nucl Med"},{"key":"2250_CR40","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1007\/s00259-017-3670-z","volume":"44","author":"WP Fendler","year":"2017","unstructured":"Fendler WP, Eiber M, Beheshti M, Bomanji J, Ceci F, Cho S, et al. 68Ga-PSMA PET\/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2017;44:1014\u201324.","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"2250_CR41","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.2967\/jnumed.115.161299","volume":"56","author":"A Afshar-Oromieh","year":"2015","unstructured":"Afshar-Oromieh A, Hetzheim H, Kratochwil C, Benesova M, Eder M, Neels OC, et al. The theranostic PSMA ligand PSMA-617 in the diagnosis of prostate cancer by PET\/CT: biodistribution in humans, radiation dosimetry, and first evaluation of tumor lesions. J Nucl Med. 2015;56:1697\u2013705.","journal-title":"J Nucl Med"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02250-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02250-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-026-02250-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:03:16Z","timestamp":1792522996000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-026-02250-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":41,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["2250"],"URL":"https:\/\/doi.org\/10.1007\/s12149-026-02250-9","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,1]]},"assertion":[{"value":"25 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}